Connection
Prabhat Mishra to Humans
This is a "connection" page, showing publications Prabhat Mishra has written about Humans.
|
|
Connection Strength |
|
|
|
|
|
0.300 |
|
|
|
-
Tiwari P, Shukla RP, Yadav K, Panwar D, Agarwal N, Kumar A, Singh N, Bakshi AK, Marwaha D, Gautam S, Rai N, Mishra PR. Exploring nanocarriers as innovative materials for advanced drug delivery strategies in onco-immunotherapies. J Mol Graph Model. 2024 May; 128:108702.
Score: 0.038
-
Singh N, Marwaha D, Gautam S, Rai N, Tiwari P, Sharma M, Shukla RP, Mugale MN, Kumar A, Mishra PR. Surface-Modified Lyotropic Crystalline Nanoconstructs Bearing Doxorubicin and Buparvaquone Target Sigma Receptors through pH-Sensitive Charge Conversion to Improve Breast Cancer Therapy. Biomacromolecules. 2023 12 11; 24(12):5780-5796.
Score: 0.038
-
Tiwari P, Shukla RP, Yadav K, Singh N, Marwaha D, Gautam S, Bakshi AK, Rai N, Kumar A, Sharma D, Mishra PR. Dacarbazine-primed carbon quantum dots coated with breast cancer cell-derived exosomes for improved breast cancer therapy. J Control Release. 2024 Jan; 365:43-59.
Score: 0.038
-
Sharma M, Panwar D, Tiwari P, Kumar A, Gautam S, Marwaha D, Rai N, Singh N, Bakshi AK, Agarwal N, Singh NKC, Mitra K, Prajapati VM, Mishra PR. Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy. Biomater Adv. 2023 Dec; 155:213672.
Score: 0.038
-
Tiwari P, Yadav K, Shukla RP, Gautam S, Marwaha D, Sharma M, Mishra PR. Surface modification strategies in translocating nano-vesicles across different barriers and the role of bio-vesicles in improving anticancer therapy. J Control Release. 2023 11; 363:290-348.
Score: 0.037
-
Sharma M, Bakshi AK, Mittapelly N, Gautam S, Marwaha D, Rai N, Singh N, Tiwari P, Agarwal N, Kumar A, Mishra PR. Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. J Control Release. 2022 06; 346:43-70.
Score: 0.034
-
Sharma M, Mittapelly N, Banala VT, Urandur S, Gautam S, Marwaha D, Rai N, Singh N, Gupta A, Mitra K, Mishra PR. Amalgamated Microneedle Array Bearing Ribociclib-Loaded Transfersomes Eradicates Breast Cancer via CD44 Targeting. Biomacromolecules. 2022 03 14; 23(3):661-675.
Score: 0.033
-
Mishra N, Sharma M, Mishra P, Nisha R, Singh P, Pal RR, Singh N, Singh S, Maurya P, Pant S, Mishra PR, Saraf SA. Transporter targeted-carnitine modified pectin-chitosan nanoparticles for inositol hexaphosphate delivery to the colon: An in silico and in vitro approach. Int J Biol Macromol. 2024 Apr; 263(Pt 2):130517.
Score: 0.010
-
Panwar D, Thakor P, Sharma M, Bakshi AK, Bhavana V, Srivastava V, Mishra PR, Singh SB, Mehra NK. Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells. Nanomedicine (Lond). 2023 06; 18(15):1005-1023.
Score: 0.009
-
Sardar A, Gautam S, Sinha S, Rai D, Tripathi AK, Dhaniya G, Mishra PR, Trivedi R. Nanoparticles of naturally occurring PPAR-? inhibitor betulinic acid ameliorates bone marrow adiposity and pathological bone loss in ovariectomized rats via Wnt/?-catenin pathway. Life Sci. 2022 Nov 15; 309:121020.
Score: 0.009
-
Ramachandran R, Bhosale V, Reddy H, Atam V, Faridi M, Fatima J, Shukla V, Khan ZA, Khan H, Singh V, Negi MPS, Srivastava M, Srivastava AK, Tripathi CB, Ghosh N, Majumdar N, Tripathi RK, Rath SK, Mishra PR, Sharma S, Kundu TK. Phase III, Randomized, Double-blind, Placebo controlled trial of Efficacy, Safety and Tolerability of Antiviral drug Umifenovir vs Standard care of therapy in non-severe COVID-19 patients. Int J Infect Dis. 2022 Feb; 115:62-69.
Score: 0.008
-
Singh PK, Raman N, Singh VK, Akhtar S, Mishra P, Sharma S. Cone-beam Computed Tomographic Evaluation of the Anatomical Changes of Temporomandibular Joint Use of Pre-post Dentures: A Time-control Study. J Contemp Dent Pract. 2020 Dec 01; 21(12):1354-1360.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|